ArticleNature communications2016
Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming.
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 129 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed.
- Proteomics of heterogeneous megakaryocytes identifies JI051 as an enhancer of platelet biogenesis.Life science alliance · 2026Article
- Are Platelet Volume, Density, and the Homeostatic Blueprint the Missing Link in Platelet-Rich Plasma Therapies? An Evidence-Based Narrative Review.Journal of clinical medicine · 2026Review
- Temporal Lysophosphatidic Acid Supplementation Enhances Megakaryocyte Differentiation and Platelet Production From Human Hematopoietic Progenitors.Cell biology international · 2026Article
- Generation and single-cell characterization of functional megakaryocytes derived from umbilical cord blood.Stem cell research & therapy · 2026Article
- Epigenome editing of human hematopoietic stem cells enables sustained and reversible thrombosis prevention.bioRxiv : the preprint server for biology · 2026Article
- Redox Regulation of Megakaryocyte Differentiation and Platelet Biogenesis.Antioxidants (Basel, Switzerland) · 2026Review
- Collagen nanofiber reinforced alginate hydrogel tube microbioreactors for cell culture.Frontiers in bioengineering and biotechnology · 2026Article
- Proteomic Validation of MEG-01-Derived Extracellular Vesicles as Representative Models for Megakaryocyte- and Platelet-Derived Extracellular Vesicles.Biomolecules · 2025Article
- Heterozygous nonsenseResearch and practice in thrombosis and haemostasis · 2025Article
- Emerging Roles of Megakaryocytes in Immune Regulation and Potential Therapeutic Prospects.Cells · 2025Review
- Production of plateletsHaematologica · 2025Article
- Notch2 Deletion Compromises Epithelial Integrity and Enamel Formation in Rodent Incisors.Cells · 2025Article
- Cell-based artificial platelet production: historical milestones, emerging trends, and future directions.Blood research · 2025Review
- Uniform impact on individual megakaryocytes is essential for efficient in vitro platelet production.Scientific reports · 2025Article
- Review
- The effect of decitabine on human induced pluripotent stem cells (hiPSCs) derived CD34American journal of stem cells · 2025Article
- Association of microtubule destabilization with platelet yields in terminally differentiating hiPSC-derived megakaryocyte lines.PloS one · 2025Article
- Highly efficient generation of mature megakaryocytes and functional platelets from human embryonic stem cells.Stem cell research & therapy · 2024Article
- Platelet Storage-Problems, Improvements, and New Perspectives.International journal of molecular sciences · 2024Review
- Generating human bone marrow organoids for disease modeling and drug discovery.Nature protocols · 2024Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
22 authors.
Funding
Abstract
The production of megakaryocytes (MKs)--the precursors of blood platelets--from human pluripotent stem cells (hPSCs) offers exciting clinical opportunities for transfusion medicine. Here we describe an original approach for the large-scale generation of MKs in chemically defined conditions using a forward programming strategy relying on the concurrent exogenous expression of three transcription factors: GATA1, FLI1 and TAL1. The forward programmed MKs proliferate and differentiate in culture for several months with MK purity over 90% reaching up to 2 × 10(5) mature MKs per input hPSC. Functional platelets are generated throughout the culture allowing the prospective collection of several transfusion units from as few as 1 million starting hPSCs. The high cell purity and yield achieved by MK forward programming, combined with efficient cryopreservation and good manufacturing practice (GMP)-compatible culture, make this approach eminently suitable to both in vitro production of platelets for transfusion and basic research in MK and platelet biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.